Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2014. The report serves as a notification of a transaction involving a Person Discharging Managerial Responsibility (PDMR) in accordance with the Disclosure and Transparency Rules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding executive compensation vesting rather than a financial results report.
Material Changes
The material event reported is the vesting of 25% of a Deferred Investment Award Plan made on June 2, 2008, for Mr. S A Hussain. This transaction resulted in a cash payment of 1,599.00 pence per share for 12,678.483 notional Ordinary shares, scheduled for June 20, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details the specific share transaction and the notification date of June 5, 2014.
Key Facts for Investor Verification
- Executive Transaction: Mr. S A Hussain received a cash payment related to the vesting of notional shares.
- Payment Details: 1,599.00 pence per share on 12,678.483 notional Ordinary shares.
- Timing: Vesting occurred on June 2, 2014; payment date is June 20, 2014.
- Regulatory Basis: Filed under Rule 13a-16/15d-16 and Disclosure and Transparency Rules paragraph 3.1.4R(1)(a).